In 2012, AbbVie's (NYSE:ABBV) Humira brought in $9.3 billion in total sales and was the best selling drug in the world. But did the autoimmune disease drug, which accounts for more than half of AbbVie's sales, keep its crown in 2013?
In the following slideshow, we reveal last year's three best-selling drugs. Blockbusters from powerhouses Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), and Merck (NYSE:MRK) all made the list.
One high-conviction stock pick for 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.